ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MDWD MediWound Limited

15.94
-1.05 (-6.18%)
After Hours
Last Updated: 16:02:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 106,829
Bid Price 15.20
Ask Price 17.70
News -
Day High 16.99

Low
7.10

52 Week Range

High
18.75

Day Low 15.47
Company Name Stock Ticker Symbol Market Type
MediWound Limited MDWD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.05 -6.18% 15.94 16:02:00
Open Price Low Price High Price Close Price Prev Close
16.95 15.47 16.99 15.94 16.99
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,646 106,829 $ 16.34 $ 1,745,403 - 7.10 - 18.75
Last Trade Time Type Quantity Stock Price Currency
16:00:00 436 $ 15.77 USD

MediWound Limited Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
113.52M 7.24M - 18.9M -6.72M -0.93 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

MediWound News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MDWD Message Board. Create One! See More Posts on MDWD Message Board See More Message Board Posts

Historical MDWD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.6518.7515.3117.25124,7680.291.85%
1 Month16.0018.7513.565615.78109,456-0.06-0.38%
3 Months12.8218.7511.0415.2673,9793.1224.34%
6 Months8.2118.757.4513.9348,5917.7394.15%
1 Year12.6018.757.1012.7632,7503.3426.51%
3 Years34.9343.547.1020.32110,718-18.99-54.37%
5 Years34.2343.547.1022.20104,301-18.29-53.43%

MediWound Description

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.

Your Recent History

Delayed Upgrade Clock